The Cigna Group Stock Outlook: Is Wall Street Bullish or Bearish?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: NASDAQ.COM
Cigna Group Overview: Cigna Group, a major health services company with a market cap of $84.3 billion, has seen its stock decline by 13.5% over the past year, despite a 9.3% increase year-to-date. The company's performance has been affected by negative sentiment towards health insurers and government actions impacting its Evernorth division.
Analyst Ratings and Projections: Analysts maintain a consensus rating of "Strong Buy" for Cigna, with a mean price target suggesting a potential upside of 25.1% to 34.8%. The company is projected to achieve an 8.6% increase in non-GAAP earnings for the current fiscal year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 268.630
Low
300.00
Averages
335.63
High
378.00
Current: 268.630
Low
300.00
Averages
335.63
High
378.00
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cigna Group Foundation Expands Impact Fund to Memphis
- Funding Opportunity: The Cigna Group Foundation has announced the expansion of its Impact Fund to Memphis, allowing nonprofits to apply for up to $250,000 in two-year grants to support adult health improvement projects, with applications due by May 15, 2025, and funding starting from December 1, 2026, through December 1, 2028.
- Community Engagement: This expansion aims to partner with local organizations to reduce health barriers and improve access to health services, reflecting the Foundation's commitment to the Memphis community, particularly in addressing chronic diseases and health disparities.
- Historical Investment: Since 2024, the Foundation has invested over $6 million in 29 nonprofit organizations across Connecticut, Missouri, and Texas, demonstrating its ongoing efforts to improve health outcomes and address social drivers of health.
- Employee Volunteerism: In 2025, Cigna directed nearly $1.8 million in charitable efforts across Tennessee, with over 4,800 employees volunteering more than 6,700 hours, indicating the company's active involvement in promoting community health and well-being.
See More
Cigna Group Expands Impact Fund to Memphis
- Funding Opportunity: The Cigna Group Foundation announces the expansion of its Impact Fund to Memphis, allowing nonprofits to apply for up to $250,000 in two-year grants aimed at supporting projects that improve health services and address local health barriers.
- Community Engagement: The foundation directed nearly $1.8 million in support across Tennessee in 2025, with over 4,800 employees volunteering more than 6,700 hours, demonstrating the company's ongoing commitment to local communities and their needs.
- Health Challenges: Residents in Memphis face higher rates of chronic conditions such as diabetes and heart disease, compounded by a lack of affordable primary care services, and the foundation's efforts aim to improve this situation through funding and resources.
- Long-term Impact: Through grants and annual convenings, nonprofits will collaborate with health experts to share insights and strengthen collective impact, ensuring that project outcomes are effectively assessed in terms of improved access to primary care services and healthy food availability.
See More
Cigna Group to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: The Cigna Group will release its Q1 2026 financial results on April 30, 2026, no later than 6:30 a.m. ET, reflecting the company's commitment to transparency.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on the same day, with participants encouraged to dial in by 8:15 a.m. ET to ensure timely access to financial information, thereby enhancing investor confidence.
- Replay and Webcast Availability: A replay of the conference call will be available from 12:30 p.m. ET on April 30 until 10:59 p.m. ET on May 14, and the call will also be accessible via a live webcast on the company's website, further improving information accessibility.
- Company Background: The Cigna Group is a global health company focused on improving health through innovative solutions, maintaining over 185 million customer relationships worldwide, showcasing its extensive influence in the global market.
See More
Cigna Group to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: The Cigna Group will release its Q1 2026 financial results on April 30, 2026, no later than 6:30 a.m. ET, demonstrating the company's commitment to transparency and timely communication with stakeholders.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on the same day, with participants encouraged to dial in by 8:15 a.m., reflecting the company's focus on investor relations and effective information dissemination.
- Replay and Webcast Availability: A replay of the conference call will be accessible from 12:30 p.m. ET on April 30 until 10:59 p.m. ET on May 14, and the call will also be available via live internet webcast, enhancing investor engagement and access to information.
- Investor Relations Information: Cigna Group will provide a news release and financial supplement on its website's Investor Relations section, ensuring investors have timely access to the latest updates, which underscores the company's commitment to transparency and investor communication.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
Cigna Group Foundation Expands Impact Fund to Memphis
- Funding Opportunity: The Cigna Group Foundation has announced the expansion of its Impact Fund to Memphis, allowing nonprofits to apply for up to $250,000 in two-year grants to support adult health improvement projects, with applications due by May 15, 2025, and funding starting from December 1, 2026, through December 1, 2028.
- Community Engagement: This expansion aims to partner with local organizations to reduce health barriers and improve access to health services, reflecting the Foundation's commitment to the Memphis community, particularly in addressing chronic diseases and health disparities.
- Historical Investment: Since 2024, the Foundation has invested over $6 million in 29 nonprofit organizations across Connecticut, Missouri, and Texas, demonstrating its ongoing efforts to improve health outcomes and address social drivers of health.
- Employee Volunteerism: In 2025, Cigna directed nearly $1.8 million in charitable efforts across Tennessee, with over 4,800 employees volunteering more than 6,700 hours, indicating the company's active involvement in promoting community health and well-being.
See More
Cigna Group Expands Impact Fund to Memphis
- Funding Opportunity: The Cigna Group Foundation announces the expansion of its Impact Fund to Memphis, allowing nonprofits to apply for up to $250,000 in two-year grants aimed at supporting projects that improve health services and address local health barriers.
- Community Engagement: The foundation directed nearly $1.8 million in support across Tennessee in 2025, with over 4,800 employees volunteering more than 6,700 hours, demonstrating the company's ongoing commitment to local communities and their needs.
- Health Challenges: Residents in Memphis face higher rates of chronic conditions such as diabetes and heart disease, compounded by a lack of affordable primary care services, and the foundation's efforts aim to improve this situation through funding and resources.
- Long-term Impact: Through grants and annual convenings, nonprofits will collaborate with health experts to share insights and strengthen collective impact, ensuring that project outcomes are effectively assessed in terms of improved access to primary care services and healthy food availability.
See More
Cigna Group to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: The Cigna Group will release its Q1 2026 financial results on April 30, 2026, no later than 6:30 a.m. ET, reflecting the company's commitment to transparency.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on the same day, with participants encouraged to dial in by 8:15 a.m. ET to ensure timely access to financial information, thereby enhancing investor confidence.
- Replay and Webcast Availability: A replay of the conference call will be available from 12:30 p.m. ET on April 30 until 10:59 p.m. ET on May 14, and the call will also be accessible via a live webcast on the company's website, further improving information accessibility.
- Company Background: The Cigna Group is a global health company focused on improving health through innovative solutions, maintaining over 185 million customer relationships worldwide, showcasing its extensive influence in the global market.
See More
Cigna Group to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: The Cigna Group will release its Q1 2026 financial results on April 30, 2026, no later than 6:30 a.m. ET, demonstrating the company's commitment to transparency and timely communication with stakeholders.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on the same day, with participants encouraged to dial in by 8:15 a.m., reflecting the company's focus on investor relations and effective information dissemination.
- Replay and Webcast Availability: A replay of the conference call will be accessible from 12:30 p.m. ET on April 30 until 10:59 p.m. ET on May 14, and the call will also be available via live internet webcast, enhancing investor engagement and access to information.
- Investor Relations Information: Cigna Group will provide a news release and financial supplement on its website's Investor Relations section, ensuring investors have timely access to the latest updates, which underscores the company's commitment to transparency and investor communication.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
